Ensysce Biosciences (ENSCW) Interest Coverage Ratio (2020 - 2025)
Ensysce Biosciences (ENSCW) reported Interest Coverage Ratio of 587.39 for Q3 2025, down 470.16% year-over-year from 158.69 in Q3 2024, and down 6.03% quarter-over-quarter from 553.96 in Q2 2025.
Ensysce Biosciences (ENSCW) Interest Coverage Ratio (2020 - 2025) Analysis & Trends
Ensysce Biosciences (ENSCW) has 6 years of Interest Coverage Ratio data on file, last reported at 587.39 in Q3 2025.
- Interest Coverage Ratio for Q3 2025 came in at 587.39, down 470.16% year-over-year; the trailing twelve-month figure through Sep 2025 was 721.71 (down 18482.01% YoY), and the FY2024 annual result was 5.25, up 82.66% from the prior year.
- Interest Coverage Ratio fell to 587.39 in Q3 2025 per ENSCW's latest filing, from 553.96 in the prior quarter.
- Over five years, Interest Coverage Ratio peaked at 158.69 in Q3 2024 and troughed at 2036.38 in Q4 2022.
- A 5-year average of 565.25 and a median of 336.84 in 2023 frame the typical range for Interest Coverage Ratio.
- The sharpest annual moves came in 2022 and 2024: Interest Coverage Ratio slumped 41098.85% in 2022, then jumped 144.83% in 2024.
- A 5-year view of Interest Coverage Ratio shows it stood at 160.71 in 2021, then plunged by 1167.14% to 2036.38 in 2022, then soared by 99.55% to 9.15 in 2023, then tumbled by 20402.4% to 1876.43 in 2024, then jumped by 68.7% to 587.39 in 2025.
- Business Quant data shows ENSCW's Interest Coverage Ratio at 587.39 in Q3 2025, 553.96 in Q2 2025, and 510.25 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 3.58 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 11.50 |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -258.33 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 547.67 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 11.79 |
| 10 | Ensysce Biosciences | - | - | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -587.39 |
| Jun 30, 2025 | -553.96 |
| Mar 31, 2025 | -510.25 |
| Dec 31, 2024 | -1,876.43 |
| Sep 30, 2024 | 158.69 |
| Jun 30, 2024 | -70.94 |
| Mar 31, 2024 | -1.48 |
| Dec 31, 2023 | -9.15 |
| Sep 30, 2023 | -353.94 |
| Mar 31, 2023 | -1,710.91 |
| Dec 31, 2022 | -2,036.38 |
| Sep 30, 2022 | -1,268.43 |
| Jun 30, 2022 | -186.74 |
| Mar 31, 2022 | -319.74 |
| Dec 31, 2021 | -160.71 |
| Sep 30, 2021 | -684.78 |
| Jun 30, 2021 | -0.45 |
| Mar 31, 2021 | -1.51 |
| Dec 31, 2020 | -4.41 |
| Sep 30, 2020 | -1.87 |